The association between baseline differences in vasculature and the immune system with ICI response has been validated in several solid tumor types, including melanoma and gastric cancer, and the combination of anti-VEGF agents and immunotherapy has seen positive results in preclinical models of SCLC[101,108-110]. Here, VEGFA is linked to small cell lung carcinoma.